Scientists stimulate immune system, stop cancer growth

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune system's natural cancer-killing T-cells and caused primary tumors and metastatic tumors in the liver to shrink.

LIGHT is an immune-stimulating chemical messenger previously found to have low levels of expression in patients with colon cancer metastases.

The results are published in Cancer Research.

Colon cancer is the second-leading cause of cancer-related death in the U.S. and, despite advances in treatment, long-term survival of patients with liver metastases is rare.

"For most patients with colon cancer that has spread to the liver, current treatments are palliative and not curative," says Dr. Ajay Maker, associate professor of surgery in the UIC College of Medicine and corresponding author on the paper. "And while studies have suggested that immunotherapy may be a promising approach for advanced cancers, the use of such treatments for advanced gastrointestinal metastases have not yet been very successful."

Maker, a surgical oncologist, says that this study is exciting because it looks at an immunotherapy intervention for a previously unresponsive gastrointestinal cancer. The intervention, he says, essentially trains the immune system to recognize and attack the tumor, and to protect against additional tumor formation - a significant issue in colon cancer.

Maker and his colleagues established colon cancer tumors in a mouse model, in which the animals had an intact and unedited immune system. Once tumors were sizable, the mice were randomized into two groups - one group had the cytokine LIGHT turned on in the tumors, and the other served as a control group for comparison.

Tumors exposed to LIGHT showed an influx of T-cells that resulted in rapid and sustained diminishment in size, even after expression of the cytokine stopped. In mice with liver metastases, expression of LIGHT similarly provoked a potent immune response that resulted in a significant decrease in tumor burden.

"We demonstrated that delivery of a therapeutic immune-stimulating cytokine caused T-cells to traffic to tumors and to become activated tumor-killing cells," Maker said. "This activity is especially exciting because it resulted in a profound anti-tumor immune response without any other chemotherapy or intervention. The treatment manipulates our natural defenses to fight off the tumor in the same way it has been trained to attack other foreign invaders in our body."

"Not only did we find that LIGHT expression promoted tumor regression, upon further study we also identified the specific type of T-cell - CD8 - that was responsible for shrinking the tumor," Maker said. "These findings are powerful and have great clinical potential."

The study was funded by grant number K08CA190855 from the National Cancer Institute, one of the National Institutes of Health.

Guilin Qiao, Jianzhong Qin, Nicholas Kunda, Jed Calata, Dolores Mahmud, Peter H. Gann, Yang-Xin Fu, Steven A. Rosenberg, Bellur s Prabhakar and Ajay V Maker.
LIGHT elevation enhances immune eradication of colon cancer metastases.
Cancer Res March 1 2017, doi: 10.1158/0008-5472.CAN-16-1655.

Most Popular Now

FDA awards 15 grants for clinical trials to stimul…

The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to...

A need for bananas? Dietary potassium regulates ca…

Bananas and avocados - foods that are rich in potassium - may help protect against pathogenic vascular calcification, also known as hardening of the arteries. University ...

Amgen and CytomX Therapeutics announce strategic c…

Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The co...

Roche launches NAVIFY Tumor Board solution to prov…

Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-...

Tagrisso granted breakthrough therapy designation …

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatm...

Pfizer launches novel programs to put important su…

Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer...

Novartis and UC Berkeley collaborate to tackle 'un…

Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pu...

Printed meds could reinvent pharmacies, drug resea…

A technology that can print pure, ultra-precise doses of drugs onto a wide variety of surfaces could one day enable on-site printing of custom-dosed medications at pharma...

Amgen and Simcere announce strategic collaboration…

Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Th...

IDF and Novo Nordisk launch first-ever global surv…

To mark World Heart Day today, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigat...

FDA awards six grants for natural history studies …

The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to i...

Indian government needs to do more to tackle risin…

In India, the sale of antibiotics requiring the tightest control and regulation is rising the fastest, according to an analysis by researchers at Queen Mary University of...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]